FDA approves new drug combo for metastatic prostate cancer

The FDA has approved Pfizer’s talazoparib (Talzenna) in combination with enzalutamide for adults with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with homologous recombination repair gene mutations. The approval was based on the TALAPRO-3 trial of 599 patients, according to an Oct. 26 FDA notice. Patients were randomized 1:1 to receive enzalutamide plus either […] The post FDA approves new drug combo for metastatic prostate cancer appeared first on Beck...